---
schema_version: "secwatch.filing_event.v1"
accession: "0001048477-24-000066"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2024-04-24T23:59:59+00:00"
generated_at: "2026-06-03T09:14:33.797722+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin Q1 revenue $649M (+9% YoY); raises non-GAAP EPS and margin guidance

## Summary
- GAAP diluted EPS $0.46 (+70% YoY); Non-GAAP diluted EPS $0.71 (+18% YoY).
- VOXZOGO revenue $153M (+74% YoY); over 3,100 children treated (+102% YoY).
- Full-year 2024 total revenue reaffirmed; non-GAAP margin and EPS guidance raised on $35-40M net OpEx savings.
- R&D portfolio prioritized: accelerated BMN 333, BMN 349, BMN 351; discontinued BMN 331, 255, 355, 365.

## SEC filing metadata
- accession: 0001048477-24-000066
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2024-04-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/0001048477-24-000066-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/bmrn-20240424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001048477-24-000066
- JSON: https://secwatch.observer/filing/0001048477-24-000066.json
- Plain text: https://secwatch.observer/filing/0001048477-24-000066.txt

## Key facts
- Earnings Releases
  BIOMARIN PHARMACEUTICAL INC reported first quarter ended March 31, 2024 results: revenue $648.8 million, net income $88.7 million, EPS $0.46. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2024
  - Revenue: $648.8 million
  - Net income: $88.7 million
  - EPS: $0.46
  - Guidance: reaffirmed
  - Result: reported results
  source text: Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803 BioMarin Reports Record Financial Results for the First Quarter 2024 First Quarter 2024 Total Revenues of $649 Million (+9% Y/Y and +13% at Constant Currency Y/Y); GAAP Diluted Earnings per Share (EPS) of $0.46 (+70% Y/Y) and Non-GAAP Diluted Earnings per Share of $0.71 (+18% Y/Y) VOXZOGO ® Net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1048477/000104847724000066/0001048477-24-000066-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.